Expanding gene panel beyond known breast/ovarian cancer genes does not add any clinic

[News]

Running large, multi-gene sequencing panels to assess cancer risk is a growing trend in medicine as the price of the technology declines and more precise approaches to cancer care gain steam. The tests are particularly common among breast and ovarian cancer patients. However, questions remain about the growing list of mutations and their suspected, but unproven association with breast and ovarian cancer risk.

More... (http://www.news-medical.net/news/20160506/Expanding-gene-panel-beyond-known-breastovarian-cancer-genes-does-not-add-any-clinical-benefit.aspx)